Women's Health Diagnostic Platform
Likely syndromic panels for infections (e.g., STIs, UTIs)
DevelopmentActive
Key Facts
Indication
Likely syndromic panels for infections (e.g., STIs, UTIs)
Phase
Development
Status
Active
Company
About Nanopath
Nanopath is a private, pre-revenue diagnostics company founded in 2018 and based in Cambridge, Massachusetts. The company is commercializing a novel, cartridge-and-reader diagnostic platform that uses surface plasmon resonance (SPR) biosensors to deliver lab-quality, multiplexed results in 10-15 minutes at the point of care, initially targeting women's health. Backed by NIH and NSF grants and led by a technically deep team, Nanopath aims to disrupt the molecular diagnostics paradigm by eliminating the need for complex sample preparation and amplification, enabling same-visit clinical decision-making.
View full company profile